BioTech Medics, Inc. Exploring Manchester England European Distribution Site November 28, 2006
Dallas, TX – BioTech Medics, Inc., (Pinksheets: BTMD) announced it is exploring opening a satellite distribution center and UK offices near the Manchester International Airport, England. The purpose for these offices will be to sell and distribute the patented SHBAN Products. The Manchester Airport area provides a convenient distribution point for SHBAN customers throughout England, Europe and the Middle East.
Earlier this year BioTech received SHBAN test results from Retroscreen Virology, at the University of London, Queen Mary’s School of Medicine, London. BioTech had conducted an independent verifiable study to determine the efficacy of virucidal SHBAN Solution against Avian HSN1 Influenza NIBRG-14 Virus (also known as the Avian Bird Flu).
The SHBAN Solution was clinically proven with its anti-viral properties to topically kill the Avian Influenza virus. But more significantly, SHBAN did so at such low concentrates that “there was no cytotoxicity observed on the MDCK cell line after treatment”.
SHBAN is superior to most other anti-viral and anti-bacterial disinfectants because SHBAN is 1) longer lasting, it does not evaporate within one minute after application (as compared to a popular alcohol based sanitizer); 2) it is non-toxic when used as directed on humans and animals; 3) it is non-staining, non-bleaching and 4) has no harmful or toxic odors. Most EPA approved disinfectant products in the USA cannot make all of these claims.
BioTech will be selling SHBAN SOLUTION in 3 0z. Travel Anywhere Hand Sanitizer Spray Bottles, 32 Oz. Home and Office Handy Bottles and 5 gal. Commerical Units.
Contact: Investor Relations 1-800-200-2458
Safe Harbor: Forward-Looking Statements.
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). “Conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks, uncertainties and results could differ materially from those expressed in the forward-looking statements. The statements above have not been evaluated by the FDA. The SHBAN product mentioned is not intended to diagnose, treat or cure any disease.
BioTech Medics, Inc. CEO Keith Houser Featured LIVE on MN1Radio; Topics Include the Patented SHBAN Bird Flu Virus Pandemic Solution
DALLAS, TX -- (MARKET WIRE) -- 06/16/2006 -- BioTech Medics, Inc. (PINKSHEETS: BTMD) announces that Market News First (http://www.mn1.com/) will be interviewing Keith Houser, CEO, "live" on their "MN1Radio Morning Program" Monday, June 19, at 9:30AM-CDST.
Market News First's one-on-one interviews with the Presidents and CEOs of microcap companies, broadcast on Market News First's website, delivers answers to the questions that microcap investors would ask, such as the companies' present conditions and future plans. This interview is not a paid endorsement of the company, but a live, non-compensated news event.
Interested investors who would like to hear the live news event can log onto MN1Radio's web site listed above and click on Monday's daily morning interview listing.
Mr. Houser was briefly featured on MN1Radio on June 9. Since that interview, according to Mark Gage, MN1Radio has received a large number of inquiries over BioTech Medics and the staff thought it best to bring Mr. Houser back to MN1Radio and do a more in-depth Q&A session.
One Hot Topic to be addressed is "How are the patented topical SHBAN disinfectant solution tests coming along concerning the effectiveness of SHBAN on the Avian Bird Flu Virus?" BioTech announced over a week ago: "We are confident that the SHBAN solution has anti-viral properties that will kill the Avian Influenza virus upon contact without harming humans, animals and the environment," said Delton Carroll, President & CEO of FHJ Scientific and Advisor.
BioTech Medics is a multi-faceted 21st Century Alternative Medicine company offering drug-free and surgery-free medical therapeutic laser treatments at 5 Pain Management & Wellness Centers in the USA (more opening soon).
Safe Harbor for Forward-Looking Statements.
This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements.
Contact:
Keith Houser
CEO
Phone: 972-274-5533
SOURCE: BioTech Medics, Inc.
DALLAS, August 3, 2005 /PRNewswire-FirstCall/ -- Keith Houser, CEO of BioTech Medics, Inc., (OTC Pink Sheets: BTMD) announced today that BTMD in cooperation with Spectrum Laser & Technology of Colorado Springs will be attending and exhibiting the NeuroLaseTM Therapeutic Medical Device at the 2005-16th Annual Clinical Meeting of the American Academy of Pain Management, September 22-25, at the Manchester Grand Hyatt in San Diego, California.
The Academy anticipates up to 1,000 pain management clinicians to attend the meetings. The overall purpose of the Annual Clinical Meeting is to educate pain management clinicians and encourage open communication among them. Attendees will have an opportunity to learn about and personally experience the NeuroLase.
The American Academy of Pain Management is a nonprofit organization dedicated to serving a broad range of clinicians treating people with pain. Founded in 1988, the Academy now has approximately 6,000 members and is the largest interdisciplinary pain organization in the United States.
The NeuroLase is one of the most powerful USA - Class 3 B Medical Lasers cleared for the temporary reduction of muscle, skeletal or arthritic pain over the entire body.
“We are getting more calls from doctors around the USA desiring information about the NeuroLase. Patients who have benefited from being treated for pain relief with the NeuroLase are getting the word out as to the safe, drug-free and surgery-free pain therapy”, said Mr. Houser. “With our ability to offer 95% financing, the decision for a medical practitioner to acquire the laser becomes easier.”
For More Information Contact BioTech Medics at 972-274-5533 or on the Internet at: http://www.biotechmedics.com
Safe Harbor for Forward-Looking Statements
This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, when used in the preceding discussion, the words "plan," "confident that," " believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the company to have adequate financing, market conditions, the general acceptance of the Company's products and technologies, competitive factors, timing, and other risks described in various Company publications.
SOURCE BioTech Medics, Inc.
/CONTACT: BioTech Medics, Inc., +1-972-274-5533
/Web site: http://www.biotechmedics.com
|
